COVID-19 Experimental Drug Treatments Can Go Terribly Wrong

We want to avoid having a thalidomide-like incident in the United States.

by Eric Holdeman / March 24, 2020

I'm old enough to remember the stories of Japanese women giving birth to babies with various birth defects. Fortunately for women here in the United States, the FDA prevented the sale of the drug. 

Today we hear talk of experimenting with different drugs to treat the coronavirus. We need to leave that up to the scientists and the Federal Drug Administration. Don't self-treat!

See note below from Wikipedia entry on thalidomide.

When first released, thalidomide was promoted for anxietytrouble sleeping, "tension", and morning sickness.[6][9] While initially deemed to be safe in pregnancy, concerns regarding birth defects were noted in 1961 and the medication was removed from the market in Europe that year.[6][5] The total number of people affected by use during pregnancy is estimated at 10,000, of which about 40% died around the time of birth.[6][3] Those who survived had limb, eye, urinary tract, and heart problems.[5] Its initial entry into the US market was prevented by Frances Kelsey at the FDA.[9] The birth defects of thalidomide led to the development of greater drug regulation and monitoring in many countries.[9]

Platforms & Programs